Pfizer licenses Kosan's motilin agonists
Cancer drug company Kosan Biosciences licensed Pfizer exclusive worldwide rights to its preclinical KOS2187 and other motilin agonists for gastrointestinal disorders.
- Includes Contract
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com